Maple 5-Amino-1MQ is a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) that rescues intracellular NAD+ and S-adenosylmethionine (SAM) levels by blocking the enzyme responsible for their depletion. In preclinical rodent models, this compound has reversed diet-induced obesity, reduced white adipose tissue mass, improved plasma lipid profiles, and enhanced skeletal muscle regeneration, all without altering food intake. It represents one of the most studied small-molecule approaches to metabolic reprogramming through the NNMT/NAD+ axis.
What Is NNMT and Why Does It Matter for Metabolic Research?
Nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1) is a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (vitamin B3), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). This reaction sits at a critical metabolic junction: it simultaneously depletes two substrates essential for cellular energy and epigenetic regulation. SAM is the universal methyl donor required for DNA methylation, histone modification, and polyamine biosynthesis. Nicotinamide is the primary precursor for NAD+ synthesis through the salvage pathway, the dominant route by which mammalian cells maintain their NAD+ pool.
When NNMT is overexpressed, as observed in the adipose tissue and liver of obese and diabetic individuals, it creates a metabolic drain. NAD+ levels fall, impairing mitochondrial oxidative phosphorylation and sirtuin-dependent deacetylation reactions. SAM depletion simultaneously disrupts the methylation landscape, altering gene expression patterns that govern lipogenesis and energy expenditure. The landmark 2014 study published in Nature by Kraus et al. demonstrated that antisense oligonucleotide knockdown of NNMT in white adipose tissue of diet-induced obese mice reduced relative adiposity by approximately 47% and body weight by roughly 7% within 10 days, while increasing both SAM and NAD+ concentrations in fat tissue (Nature 508, 258-262, 2014, n=8-10 per group). This established NNMT as a druggable target for metabolic disease research.
5-Amino-1MQ: Mechanism of NNMT Inhibition
5-Amino-1MQ (5-amino-1-methylquinolinium, CAS 42816-54-2) is a small-molecule quinolinium derivative, not a peptide in the classical sense, but widely studied alongside research peptides due to its role in the NAD+ metabolic axis that intersects with compounds like NAD+ and MOTS-c. Researchers at the University of Texas Medical Branch (UTMB) first characterized 5-amino-1MQ as a selective NNMT inhibitor while screening quinolinium-based compounds for their ability to competitively occupy the NNMT active site.
The compound works by mimicking the quaternary nitrogen structure of 1-methylnicotinamide, the product of the NNMT reaction, and competitively binding the enzyme’s substrate pocket. Unlike genetic knockdown approaches, 5-amino-1MQ is membrane-permeable and reaches intracellular NNMT without requiring transfection or viral delivery. This pharmacological accessibility made it the first NNMT inhibitor suitable for in vivo metabolic studies in whole-animal models. By blocking NNMT catalytic activity, 5-amino-1MQ preserves the nicotinamide pool available for NAD+ salvage synthesis via nicotinamide phosphoribosyltransferase (NAMPT), while simultaneously conserving SAM for methyltransferase reactions throughout the cell.
The Neelakantan 2018 Study: Reversing Diet-Induced Obesity
The pivotal preclinical study on 5-amino-1MQ was published in Biochemical Pharmacology in 2018 by Neelakantan, Vance, Wetzel, and colleagues at UTMB (Biochem Pharmacol 147, 141-152, 2018). This study established both the in vitro and in vivo pharmacological profile of the compound across two experimental phases.
In the cell-based phase, researchers treated 3T3-L1 murine adipocytes with 5-amino-1MQ and measured intracellular metabolite concentrations. Treatment significantly reduced intracellular 1-methylnicotinamide (the NNMT product), confirming on-target enzyme inhibition. Intracellular NAD+ levels increased by 1.2 to 1.6 fold compared to untreated controls, demonstrating that blocking NNMT successfully rerouted nicotinamide toward the NAD+ salvage pathway. Lipogenic gene expression was suppressed, and adipocyte volume decreased measurably in treated cultures.
In the animal phase, diet-induced obese C57BL/6 mice received 5-amino-1MQ at 20 mg/kg three times daily via subcutaneous injection over 11 days (n=9 per group). Treated animals showed significantly reduced body weight (p<0.05) and white adipose tissue mass (p<0.01) compared to vehicle controls. Plasma total cholesterol dropped significantly (p<0.05), and adipocyte cross-sectional area was reduced with high statistical confidence (p<0.0001). Critically, food intake did not differ between treated and control groups, indicating the anti-obesity effect was driven by altered energy expenditure and lipid metabolism rather than appetite suppression. No observable adverse effects were reported across the 11-day treatment window.
Skeletal Muscle Regeneration and Satellite Cell Activation
Beyond adipose tissue, NNMT inhibition through 5-amino-1MQ has shown preclinical relevance in skeletal muscle research, an area that overlaps with mechanistic studies on other tissue-repair compounds such as BPC-157 peptide, particularly in the context of aging and sarcopenia. Muscle satellite cells (MuSCs), the resident stem cells responsible for post-injury muscle repair, require adequate NAD+ for proliferation and differentiation. As NNMT expression increases with age, it depletes the local NAD+ pool and impairs satellite cell activation.
In murine injury models, administration of 5-amino-1MQ increased satellite cell proliferation and fusion efficiency, producing larger regenerating myofibers and improved contractile function. Researchers observed approximately a 70% increase in muscle torque output and a roughly twofold expansion of myofiber cross-sectional area relative to untreated controls. These findings suggest that NNMT inhibition restores the metabolic environment needed for effective myogenesis by conserving nicotinamide for NAD+ salvage and modulating redox-sensitive signaling cascades that govern the transition from quiescent to activated satellite cell states.
A 2024 study extended these findings to aged mice, demonstrating that 5-amino-1MQ improved grip strength beyond what exercise alone achieved. When combined with exercise training, NNMT inhibition conferred sustained enhanced muscle performance that neither intervention produced independently. This additive effect points toward NNMT as a rate-limiting metabolic bottleneck in age-related muscle decline, distinct from the contractile and neural adaptations driven by exercise itself. For researchers studying compounds that target age-related decline, this positions 5-amino-1MQ alongside mitochondrial peptides like SS-31 (Elamipretide) and MOTS-c as tools for investigating the NAD+/mitochondrial axis in musculoskeletal aging.
The NNMT/NAD+ Axis in Cancer Research
NNMT overexpression is not limited to metabolic disease. Elevated NNMT activity has been documented across multiple tumor types, where it appears to support cancer cell proliferation through several intersecting mechanisms. A 2024 review published in International Immunopharmacology detailed how NNMT overexpression in tumor microenvironments depletes SAM, reducing histone and DNA methylation at tumor suppressor loci and promoting an epigenetically permissive state for uncontrolled growth. Simultaneously, NNMT-driven NAD+ depletion impairs PARP-mediated DNA repair and sirtuin-dependent metabolic regulation, further destabilizing cellular homeostasis. Researchers working in this space can review available compound documentation and purity data at the Maple Research documentation library.
A 2024 review in Frontiers in Pharmacology (Sun and Zhu, Front Pharmacol 15, 1410479, 2024) examined NNMT as a therapeutic target for metabolic syndrome, noting that the enzyme’s role extends across obesity, insulin resistance, non-alcoholic fatty liver disease, and oncogenesis. The authors highlighted that while small-molecule inhibitors like 5-amino-1MQ show promise, discrepancies between animal model findings and human tissue expression patterns remain a translational challenge. NNMT expression varies significantly across human tissues and disease states, and the consequences of systemic inhibition versus tissue-specific targeting are not yet fully characterized in primate models.
Key Research Findings
- In diet-induced obese mice (n=9/group), 5-amino-1MQ at 20 mg/kg TID for 11 days reduced body weight (p<0.05), white adipose mass (p<0.01), and adipocyte size (p<0.0001) without affecting food intake (Neelakantan et al., Biochem Pharmacol, 2018)
- NNMT knockdown in white adipose tissue reduced relative adiposity by ~47% and body weight by ~7% in 10 days while increasing SAM and NAD+ in fat tissue (Kraus et al., Nature, 2014, n=8-10/group)
- In 3T3-L1 adipocytes, 5-amino-1MQ increased intracellular NAD+ by 1.2 to 1.6 fold and suppressed lipogenic gene expression (Neelakantan et al., 2018)
- Murine muscle injury models showed ~70% increase in torque output and ~2x myofiber cross-sectional area with NNMT inhibition versus untreated controls
- In aged mice, 5-amino-1MQ combined with exercise improved grip strength beyond exercise alone, suggesting additive mechanisms (2024 preclinical study)
- NNMT overexpression is elevated in adipose tissue and liver of obese/diabetic humans and across multiple tumor types, with therapeutic inhibition under active investigation
Analytical Considerations for Research-Grade 5-Amino-1MQ
Because 5-amino-1MQ is a small molecule rather than a peptide, its analytical verification differs from standard HPLC-based peptide purity assessment. Identity confirmation typically relies on liquid chromatography-mass spectrometry (LC-MS) to verify the molecular ion at m/z 159.09 (corresponding to the quinolinium cation C10H11N2+) and nuclear magnetic resonance (NMR) spectroscopy for structural confirmation. Purity assessment uses reversed-phase HPLC with UV detection at 254-280 nm, where the quinoline chromophore provides strong absorbance. Researchers should verify that suppliers provide batch-specific analytical documentation covering identity, purity, and residual solvent content. At Maple Research Labs, all research compounds undergo independent third-party COA verification through Janoshik Analytical to ensure batch-specific purity data is available before any product ships to researchers.
Current Limitations and Open Questions
Despite encouraging preclinical data, several significant gaps remain in the 5-amino-1MQ research literature. No human clinical trials have been published or registered for this compound. All efficacy and safety data derive from murine models and cell culture systems, which limits direct extrapolation to human physiology. The pharmacokinetic profile in primates, including bioavailability, half-life, tissue distribution, and metabolic clearance, has not been publicly characterized.
The tissue-specificity question is particularly relevant. NNMT plays different roles across different organs. In the liver, NNMT appears to have protective functions, and systemic inhibition could produce unintended consequences that tissue-specific approaches would avoid. The 2024 Frontiers in Pharmacology review explicitly flagged discrepancies between rodent and human NNMT expression patterns as a barrier to clinical translation. Researchers sourcing compounds for NNMT inhibition studies should confirm batch-specific purity via third-party certificates of analysis before experimental use. Long-term safety data from chronic administration studies, dose-response relationships across multiple tissues, and potential interactions with other NAD+-modulating compounds (such as nicotinamide riboside, NMN, or NAD+) remain active areas of investigation.
For researchers designing studies involving NNMT inhibition, understanding these limitations is essential for proper experimental design and data interpretation. The compound’s preclinical profile is robust within defined parameters, but extrapolation beyond those parameters requires caution. Comparative studies examining 5-amino-1MQ alongside other metabolic modulators, including research peptides targeting overlapping pathways, represent a productive direction for future investigation.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.